Business
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. “Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market l
About this update from Inhibikase Therapeutics, Inc.
[{"type":"image","alt":"Inhibikase Therapeutics","displaySize":"","headline":null,"caption":"Inhibikase Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Jrx7oJ.q30fX7LRFGfs16Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52","width":300,"height":136}},"lazy":false},{"type":"text","content":"BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer.","length":388,"tagName":"p"},{"type":"text","content":"“Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market landscape, and we are delighted to welcome him to the Inhibikase team,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “As we advance IKT-001 toward a late-stage clinical trial in PAH, Tim’s insights into the PAH therapeutic landscape and connections with key thought leaders will be invaluable. We look forward to his guidance and contributions.”","length":467,"tagName":"p"},{"type":"text","content":"Mr. Pigot is an accomplished pharmaceutical industry executive with over three decades of experience in both large pharma and start up organizations. Most recently he served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company’s therapeutic candidate in PAH. Previously Mr. Pigot was Vice President of Marketing for MyoKardia, where he led commercial launch strategy for mavacamten, a first in class cardiac myosin inhibitor. Earlier in his career, Mr. Pigot held several leadership positions at Gilead Sciences and Pfizer, where he led sales, marketing, and operations for products in the PAH, cardiopulmonary, CNS and oncology therapeutic areas. Mr. Pigot earned his Bachelor of Sciences degree from the SUNY Binghamton School of Management.","length":806,"tagName":"p"},{"type":"text","content":"Abo...